Search results
Showing 16 to 30 of 66 results for ulcerative colitis
Guselkumab for treating moderately to severely active ulcerative colitis ID6237
In development [GID-TA11247] Expected publication date: TBC
Faecal calprotectin diagnostic tests for inflammatory diseases of the bowel (DG11)
Evidence-based recommendations on faecal calprotectin tests for distinguishing between inflammatory bowel diseases (such as Crohn’s disease and ulcerative
PredictSURE IBD for inflammatory bowel disease prognosis: ulcerative colitis (MIB313)
NICE has developed a medtech innovation briefing (MIB) on PredictSURE IBD for inflammatory bowel disease prognosis: ulcerative colitis .
to check for signs of bowel cancer in people aged 18 and over with ulcerative colitis or Crohn's disease (types of inflammatory bowel...
In development [GID-TA11184] Expected publication date: TBC
Spondyloarthritis in over 16s: diagnosis and management (NG65)
This guideline covers diagnosing and managing spondyloarthritis that is suspected or confirmed in adults who are 16 years or older. It aims to raise awareness of the features of spondyloarthritis and provide clear advice on what action to take when people with signs and symptoms first present in healthcare settings. It also provides advice on the range of treatments available.
Evidence-based recommendations on leukapheresis for inflammatory bowel disease. This involves removing a small number of white blood cells from the person’s blood.
View recommendations for IPG126Show all sections
Sections for IPG126
Etrolizumab for treating moderately to severely active ulcerative colitis [ID3827]
Awaiting development [GID-TA10717] Expected publication date: TBC
This is a summary of the most common accessibility changes we are making in guidelines, and why
Show all sections
This guideline covers managing Crohn’s disease in children, young people and adults. It aims to reduce people’s symptoms and maintain or improve their quality of life.
Summary of the evidence on rifaximin for treating pouchitis to inform local NHS planning and decision-making
ProciseDx point-of-care platform for inflammatory bowel disease (MIB302)
NICE has developed a medtech innovation briefing (MIB) on ProciseDx point-of-care platform for inflammatory bowel disease .
l) methotrexate in the induction of remission in mild-to-moderate ulcerative colitis unresponsive to aminosalicylates? Any explanatory...
monotherapy for the induction of remission for people with mild-to-moderate ulcerative colitis? Any explanatory notes(if applicable) To...
aminosalicylates for the induction of remission for people with moderate ulcerative colitis? Any explanatory notes(if applicable) Source...